ArticleStem cell research & therapy2026
Regenerative potential of extracellular vesicles from endometrial mesenchymal stem cells for modulating fibrosis and wound healing.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundFibrotic scarring resulting from trauma, burns, or surgery affects over 100 million people annually and is associated with functional, aesthetic, and psychological burdens. Current treatments remain inadequate, highlighting the need for novel, effective, and cell-free therapeutic strategies. Extracellular vesicle-enriched preparations derived from human endometrial mesenchymal stem cells (eMSC-EV-enriched preparations) may possess regenerative and anti-fibrotic potential, yet their roles in scar modulation and underlying mechanisms remain unclear.
methodseMSCs were isolated from human endometrial biopsies and characterized via flow cytometry and differentiation assays. The eMSC-EV-enriched preparations were obtained from conditioned medium and verified by TEM, NTA, and Western blotting. Functional assays were conducted in NIH3T3 fibroblasts to assess proliferation, migration, and transwell invasion capacity. A full-thickness cutaneous wound model and a bleomycin-induced dermal fibrosis model were used in C57BL/6 mice to evaluate tissue repair and fibrosis attenuation. Histological and molecular analyses were performed to assess collagen deposition, fibrosis-associated markers, and related signaling pathways. The potential involvement of miR-125b-5p in Smad2-related signaling was explored.
resultsThe eMSC-EV-enriched preparations displayed characteristic vesicular morphology and marker expression. Compared with BMMSC-EV-enriched preparations, eMSC-EV-enriched preparations more effectively reduced fibroblast proliferation and migration, with decreased transwell invasion capacity in vitro. In vivo, the eMSC-EV-enriched preparations enhanced wound closure, reduced collagen deposition, and were associated with improved collagen organization and an increased number of appendage-like structures. Expression of α-SMA and collagen I and III was reduced in tissues treated with the eMSC-EV-enriched preparations. Furthermore, the preparations were associated with increased miR-125b-5p levels and decreased Smad2/p-Smad2 expression, suggesting involvement of the miR-125b-5p/Smad2 axis. In the bleomycin model, the eMSC-EV-enriched preparations attenuated dermal thickening and collagen accumulation during fibrosis induction.
conclusionsOur findings indicate that eMSC-EV-enriched preparations improve repair quality and attenuate fibrosis development, potentially through modulation of fibroblast activity and involvement of the miR-125b-5p/Smad2 signaling pathway. These findings support further investigation of eMSC-EV-enriched preparations as a cell-free strategy for improving tissue remodeling in fibrotic skin conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.